Cosmetics, pharmaceutical, and biomaterials platform company Daebong LS achieved record-high cumulative revenue for the first three quarters of this year.

Daebong LS Posts Record Cumulative Revenue Through Q3 View original image

Daebong LS announced in a regulatory filing on November 16 that its consolidated revenue for the third quarter of this year was KRW 31.1 billion. Revenue rose 25% year over year, marking double-digit growth for the third consecutive quarter since the first quarter of this year. Cumulative revenue for the first three quarters reached KRW 93.8 billion, up 21% year over year.


Operating profit also rose sharply. Operating profit for the third quarter was KRW 2.7 billion, about four times the KRW 700 million recorded in the same quarter last year. Cumulative operating profit was KRW 8.4 billion, up 25% year over year.


Rising demand for cosmetic ingredients, driven by the expansion of the global K-beauty market, was central to the improved performance. In particular, since the European Union (EU) began restricting the use of cyclic silicones D4, D5, and D6 in rinse-off cosmetics in June, demand for alternative ingredients has grown among domestic brands and original design manufacturers (ODMs). As a result, orders have also increased for alternative emollients that replicate the feel of conventional silicones in hair conditioners, treatments, and skincare products.


High-performance peptide ingredients also contributed to improved profitability. As demand for home care after skin treatments such as lifting and skin boosters, as well as for anti-aging products, has expanded, sales have steadily increased for peptides that improve wrinkles and elasticity and ingredients related to skin soothing and regeneration.



A Daebong LS representative said, "These results are meaningful because they show that the ingredient technologies we have built up over the years and our diverse raw material portfolio are translating into tangible business results. Going forward, we will commercialize the results of joint development with major ODMs to increase the share of high-value-added cosmetic ingredients, while also strengthening the competitiveness of our active pharmaceutical ingredient business, sustaining our growth and improving profitability."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing